why choose us

First received: November 04, 2022

Clinical Trial: ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Brief Summary: In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxel after demonstrated progression on frontline therapy.In phase I of the study, up to 6 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy.Although safety and tolerability has been previously determined in the sarcoma population, dose de-escalations of the chemotherapies in that…

Read more